Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma
Status:
Recruiting
Trial end date:
2022-10-03
Target enrollment:
Participant gender:
Summary
This study is plan to assess the safety and efficacy of Acalabrutinib in Indian patients with
chronic lymphocytic leukaemia (CLL) and relapsed and refractory mantle cell lymphoma (MCL)